Lumiracoxib
- Generic Name
- Lumiracoxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13ClFNO2
- CAS Number
- 220991-20-8
- Unique Ingredient Identifier
- V91T9204HU
- Background
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
- Indication
For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Lumiracoxib
- Conditions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 330
- Registration Number
- NCT00267215
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 234
- Registration Number
- NCT00170781
- Locations
- 🇨🇭
For Site Information, contact Novartis Pharma AG, Basel, CH, Switzerland
🇩🇪Novartis, Nuernberg, Germany
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-10-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 419
- Registration Number
- NCT00170898
- Locations
- 🇬🇧
For site information contact, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 135
- Registration Number
- NCT00170872
52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3036
- Registration Number
- NCT00145301
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.